BioNTech SE

BioNTech SE announced it will release its financial results for the second quarter of 2026 on Tuesday, August 4, 2026. The company will also host a conference call and webcast on the same day at 8:00 a.m. ET to discuss the results and provide a corporate update. Details for registration and accessing the webcast will be made available on BioNTech's investor relations website.

BioNTech SE announced the commencement of its previously authorized share repurchase program. The company plans to buy back up to $1.0 billion in American Depositary Shares (ADSs) on the U.S. Nasdaq Global Select Market. The buyback period begins on June 8, 2026, and will run until May 6, 2027, aiming to enhance capital efficiency and maintain financial flexibility.

BioNTech SE and Bristol Myers Squibb Company announced encouraging interim Phase 2 data from the ROSETTA Lung-02 clinical trial for pumitamig (BNT327/BMS-986545) in previously untreated advanced non-small cell lung cancer (NSCLC). The investigational bispecific immunomodulator, combined with chemotherapy, demonstrated robust anti-tumor activity with high objective response rates across NSCLC subtypes and PD-L1 expression levels. The companies are advancing pumitamig into a comprehensive global Phase 3 development program.

BioNTech and Bristol Myers Squibb announced encouraging interim Phase 2 data for pumitamig (PD-L1xVEGF-A bispecific immunomodulator) plus chemotherapy in first-line non-small cell lung cancer (NSCLC). The data showed robust anti-tumor activity with high objective response rates across PD-L1 expression levels and subtypes, including 63.6% in non-squamous and 72.7% in squamous NSCLC at the lower dose. Pumitamig demonstrated a manageable safety profile and is advancing through a comprehensive global Phase 3 development program, including the actively enrolling pivotal Phase 3 part of the ROSETTA Lung-02 trial and two additional global Phase 3 trials.

BioNTech SE announced it will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Highlights include encouraging anti-tumor activity for pumitamig in first-line non-small cell lung cancer and durable anti-tumor activity with clinically meaningful overall survival for gotistobart in platinum-resistant ovarian cancer. The company's diversified oncology pipeline features over 25 Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials and novel-novel combination approaches.

BioNTech SE announced it will present new clinical data and trial updates from its late-stage oncology pipeline at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Highlights include encouraging anti-tumor activity for pumitamig in first-line non-small cell lung cancer from the ROSETTA Lung-02 trial, and durable anti-tumor activity and clinically meaningful overall survival for gotistobart in platinum-resistant ovarian cancer from the PRESERVE-004 trial. The company continues to advance its oncology pipeline with over 25 Phase 2 and Phase 3 clinical trials, including 13 pivotal trials.

BioNTech SE shareholders approved all agenda items at the 2026 Annual General Meeting, with 92% of the share capital represented. Key resolutions included expanding the Supervisory Board from six to eight members and electing Prof. Iris Löw-Friedrich and Dr. Susanne Schaffert to add expertise in clinical development and oncology. Shareholders also extended the mandates of three existing board members and re-elected Helmut Jeggle as Chairman of the Supervisory Board.

BioNTech SE held its Annual General Meeting, where shareholders approved all proposed resolutions, with 92% of the share capital represented. A key approval included expanding the Supervisory Board from six to eight members to add further expertise, aligning with the company's strengthened focus on its late-stage oncology pipeline. Prof. Iris Löw-Friedrich and Dr. Susanne Schaffert were elected as new members, bringing extensive experience in clinical development, oncology, sales, and commercialization. Additionally, the mandates of existing Supervisory Board members Helmut Jeggle, Prof. Anja Morawietz, and Prof. Rudolf Staudigl were extended, with Helmut Jeggle re-elected as Chairman.

BioNTech SE announced a new share repurchase program, authorizing the company to buy back up to $1.0 billion in American Depositary Shares (ADSs) until May 6, 2027. This program aims to enhance capital efficiency, support long-term value creation, and maintain financial flexibility, aligning with BioNTech's goal to become a multi-product company by 2030. The repurchases will be funded by existing cash resources and are expected to satisfy ordinary course of business obligations. CFO Ramón Zapata stated confidence in long-term growth and commitment to sustainable shareholder value.

BioNTech SE reported a significant decline in its financial performance for the first quarter ended March 31, 2026. Revenues decreased by 35.4% to €118.1 million, primarily due to lower COVID-19 vaccine sales. The company's net loss widened to €531.9 million, an increase of 27.9% compared to the prior year, driven by higher R&D expenses and an impairment loss of €37.7 million, mainly related to the BNT331 program. Despite the losses, BioNTech maintained a strong liquidity position with €16,763.3 million in cash, cash equivalents, and security investments.